Salgia to Help Strengthen Translational Medicine, Cancer Research Programs
Ravi Salgia, MD, PhD, is taking on two new roles to help enhance the translational medicine and cancer research programs at UChicago.
Effective October 1, 2011, Dr. Salgia will become the new vice chair for translational research for the Department of Medicine (DOM) and the new associate director for translational sciences for The University of Chicago Comprehensive Cancer Center (UCCCC).
As vice chair for translational research, Dr. Salgia will help recruit translational researchers and will be responsible for promoting translational research across the DOM. Additionally, he will play an important role in assisting DOM Chair Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, in reorganizing the DOM Research Advisory Committee and in facilitating the development of new scientific programs.
As the new associate director for translational sciences for the UCCCC, Dr. Salgia will have responsibility for overseeing and promoting translational research within the UCCCC and across The University of Chicago Medical Center cancer programs. He will work closely with UCCCC leaders to identify targeted opportunities for collaboration, the resources needed to accomplish these activities, and strategies for implementation.
“Dr. Salgia brings exceptional expertise in translational research to our cancer programs, in an era of unique opportunity in biomedical research,” said UCCCC Director Michelle M. Le Beau, PhD, Arthur and Marian Edelstein Professor of Medicine. “We welcome his leadership in identifying targeted opportunities for collaboration and programmatic growth, as well as strategies to improve our infrastructure for translational research, and to realize our strategic vision for cancer.”
Dr. Salgia received his PhD in biochemistry and biophysics in 1985, followed by his MD in 1987 from Loyola University. He completed his residency training in internal medicine at The Johns Hopkins University and his fellowship training in medical oncology at the Dana-Farber Cancer Institute. He served for 10 years on the faculty at Dana-Farber, Brigham and Women’s Hospital, and Harvard Medical School before joining the UChicago faculty in 2003 as an associate professor of medicine in the Section of Hematology/Oncology. In 2008, he was promoted to a tenured professor.
His expertise is in the areas of thoracic oncology, translational research, and basic science research. His main research interest is in the development of novel, targeted therapeutics to enhance the quality of life and survival for cancer patients. Dr. Salgia and his lab have recently identified several novel receptor tyrosine kinases that are abnormal in lung cancer. He is an expert in signal transduction, as related to growth factor receptors and oncogenes/tumor suppressor genes, and is developing novel inhibitors based on these pathways. He is also an expert in tumor and body fluid biomarkers, and is applying this knowledge to develop new serum/tumor tissue tests for thoracic oncology.